PubMed · 2004 · 40 citations · 30 references
MedicineInternal MedicinePharmacotherapyAntimicrobial PharmacotherapyPulmonary Function TestingPulmonologyAcute Exacerbation ManagementBronchodilator TherapyPulmonary InfectionsRespiratory DiseaseRespiratory InfectionsRespiratory MedicineAcute Exacerbation TreatmentChronic Bronchitis TreatmentForced Expiratory Volume AssessmentForced Expiratory Volume DeclineLung Function DeclineMacrolide TherapyProductive Cough ManagementPulmonary Exacerbations
OBJECTIVE: To develop consensus on appropriate treatment for acute exacerbation of chronic bronchitis (AECB). CHARACTERISTICS AND ETIOLOGY: Patients with chronic bronchitis have an irreversible reduction in maximal airflow velocity and a productive cough on most days of the month for 3 months over 2 consecutive years. An AECB is characterized by a period of unstable lung function with worsening airflow and other symptoms. Most (80%) cases of AECB are due to infection, with half due to aerobic bacteria. The remaining 20% are due to noninfectious causes such as environmental factors or medication nonadherence. MANAGEMENT: Supportive care should be provided to all patients, which might include removal of irritants, use of a bronchodilator, oxygen, hydration, use of a systemic corticosteroid, and chest physical therapy. Antibacterial treatment should be reserved for patients with at least 1 key symptom (ie, increased dyspnea, sputum production, sputum purulence) and 1 risk factor (ie, age > or = 65 years, forced expiratory volume in 1 second < 50% of the predicted value, > or = 4 AECBs in 12 months, 1 or more comorbidities). A newer macrolide, extended-spectrum cephalosporin, or doxycycline is appropriate for an exacerbation of moderate severity, and high-dose amoxicillin/clavulanate or a respiratory fluoroquinolone should be used for a severe exacerbation. There has been increasing antibacterial resistance by the 3 most prevalent pathogens (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis). CONCLUSION: Although all AECB patients should receive supportive care, only patients with at least 1 key symptom and 1 risk factor should receive antibiotic therapy.
30
Chronic Obstructive Pulmonary Disease Surveillance—United States, 1971–2000
David M. Mannino, David M. Homa, Lara J. Akinbami et al. · Respiratory Care · 2002 · 1.3K citations · Full text
Terence Seemungal, RHIAN HARPER-OWEN, Angshu Bhowmik et al. · American Journal of Respiratory and Critical Care Medicine · 2001 · 1K citations · Full text
Veterinary Medicine, Immunology, Immunology Of Infectious Diseases +4
Infective Exacerbations of Chronic Bronchitis
Anja Ede, Tom Schaberg, Michael S. Niederman et al. · CHEST Journal · 1998 · 375 citations · Full text